… microsphere/PVA hydrogel composites has been shown to suppress the inflammatory …
the initial acute inflammatory phase with fast releasing dexamethasone-PLGA microsphere/PVA …

… In this paper, a new dexamethasone/PLGA microsphere system is reported which … release
of dexamethasone for over 1 month. This dexamethasone/PLGA microsphere system has …

… dexamethasone/PLGA microsphere system to suppress both acute and chronic inflammatory
… proven the efficacy of PLGA microsphere delivery of an anti-inflammatory to control tissue …

… The in vivo pharmacodynamic affect of dexamethasone (ie control of inflammation at the
site) was also investigated in this study as this may affect the in vivo release kinetics. …

… PLGA-DEX NPs 0.1 mg/kg group, compared to the 5-FU group. GILZ is considered a resolution
marker of the inflammatory … that the anti-inflammatory activity of DEX is associated with …

… dexamethasone-loaded microspheres had less inflammation than control eyes and eyes
injected with blank microspheres. Inflammation … Our dexamethasone-PLGA formulation was …

… In conclusion, we expect that controlled release of DEX by this PLGA NP formulation will be
able to reduce inflammation for the local treatment of oral precancerous lesions and that the …

… In our study, SPIONs and the corticosteroid dexamethasone acetate (DXM) are co-encapsulated
into PLGA microparticles for the aim of locally treating inflammatory conditions such as …

… the anti-inflammatory and anti-fibrosis effect of DXMS/CAP@PLGA-ILs in the mouse MesPGN
model of this study. Hence, we measured the expression levels of inflammatory factors and …

… events that include acute inflammation (eg., infiltration of inflammatory cells), chronic … low
Mw PLGA and the other with high Mw PLGA. Dexamethasone release from PLGA microspheres …